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between the three transplant groups appeared in the ﬁrst 100 days
post transplant but without giving advantage to any group. Indeed,
the delay of engraftment and increased treatment-related mortality
observed after UCBT must be balanced with the higher risk of
acute GVHD after unmanipulated BMT and with the higher risk
of relapse after T-cell depleted BMT. In contrast, after day 100
posttransplant, the 3 groups achieved similar results in terms of
relapse but chronic GVHD and death occurred more frequently
with unmanipulated BMT and T-cell depleted BMT respectively.
These results justify the simultaneous search for unrelated cord
blood and unrelated bone marrow donors for children with acute
leukemia. The decision to perform cord blood transplants will be
based on the cell content of the graft, the number of HLA dispar-
ities and the urgency of the transplant.
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UNRELATED CORD BLOOD TRANSPLANTATION FOR TRANSFUSION-
DEPENDENT THALASSEMIA IN CHILDREN
Jaing, T.H., Hung, I.J., Yang, C.P. Chang Gung Children’s Hospital,
Chang Gung University, Taoyuan, Taiwan
Hematopoietic stem cell transplantation is currently the only
curative therapy for transfusion-dependent thalassemia. However,
approximately 30% of patients have unaffected HLA-identical sib-
lings to serve as donors. We investigated the feasibility of unrelated
cord blood transplantation (CBT) as a potential strategy for aug-
menting the pool of acceptable donors. Between October 2003 and
December 2004, 9 children with 	-thalassemia major received
CBT with at least 2.5  107/kg TNC from unrelated donors (0-2
of 6 HLA antigens were mismatched) and were then evaluated for
engraftment, adverse effects, and treatment outcome. Condition-
ing consisted of busulfan, cyclophosphamide, and antithymocyte
globulin, and GVHD prophylaxis of cyclosporine and methylpred-
nisolone. Median age was 3.7 years (range, 2.3-11.4 years). One
patient died of penicillin-resistant S. mitis sepsis at day 8 prior to
the “expected” time to respond. Eight of 9 patients were alive at
median follow-up of 254 days after transplantation, with complete
donor chimerism and transfusion independence. The median times
to neutrophil engraftment, RBC transfusion independence, and
platelet engraftment were 13, 34, and 45 days after transplantation,
respectively. The patients showed grade I-III acute GVHD. No
extensive chronic GVHD had developed at the latest contact. The
medical costs per-patient with CBT in Taiwan is estimated to be
approximately US$40,000 plus the cost of the cord blood unit. In
summary, our results suggest that unrelated CBT is an alternative
treatment for patients with transfusion-dependent thalassemia
lacking an HLA-matched sibling bone marrow donor, and it is
clearly cost-effective when compared to conventional treatment
with blood transfusions and iron chelation therapy.
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OUTCOMES OF UNRELATED CORD BLOOD TRANSPLANTS AND ALLO-
GENEIC RELATED HEMATOPOIETIC STEM CELL TRANSPLANTS IN CHIL-
DREN WITH HIGH-RISK ACUTE LYMPHOCYTIC LEUKEMIA
Jacobsohn, D.A., Hewlett, B., Seshadri, R., Ranalli, M., Duerst, R.,
Kletzel, M. Children’s Memorial Hospital and Feinberg School of Med-
icine, Northwestern University, Chicago, IL
Background: HSCT is commonly used for pediatric ALL pa-
tients (pts) with early relapse or other high-risk features. Given
lack of matched-sibling donors and multiple advantages of UCB as
stem cell source (less GVHD, rapid availability), we compared
outcomes of pediatric ALL pts that underwent HSCT with UCB
(4-5/6 HLA) or matched-sibling transplant (6/6 HLA).
Methods: Pts included: ALL CR2 pts who relapsed 36 mos
from diagnosis and ALL CR1 pts with 1 high-risk feature (un-
favorable karyotype, poor response to induction, age 1 yr, WBC
100,000 at diagnosis). 25% of CR1 pts in both groups had 2
high-risk features. Cytoreduction (same in both groups): Pts re-
ceived TBI 150 cGy  8 (d 
10 to 
7); VP-16 1 g/m2/day (d 
6
to 
5); cyclophosphamide 60 mg/kg/day (d 
4 to 
2). GVHD
prophylaxis: CSA, short-course MTX, and ATG d1,3,5,7
(for UCB). Grafts were not T-cell depleted.
Results: There were 23 matched-sibling (20 BM/3 PBSC) and
26 UCB recipients. Both groups had equivalent high-risk factors.
Engraftment took longer in UCB recipients. TRM and GVHD
were equal in both groups. 3 yr EFS is 60% in both groups. Age,
gender, degree of HLA-matching for UCB, acute/chronic GVHD
did not affect EFS.
Conclusions: In pediatric pts with high-risk ALL in need of
HSCT, outcome of matched-sibling HSCT and UCB transplant is
equivalent with regards to TRM, GVHD, and EFS. UCB should
be considered a standard stem cell source to use in this group when
a matched sibling is not available.
Table 1.
Matched-sibling
(n  23) UCB (n  26) p
Age diagnosis
(yrs)* 2.5 (0.3-15.4) 3.9 (0.3-11.9) 0.63
Status at
HSCT (CR1) 11 (47.8%) 10 (38.5%) 0.34
Age <1 yr 7 (30.4%) 6 (23.1%) 0.56
Karyotype
(unfavorable) 8 (34.8%) 11 (42.3%) 0.79
Neutrophil
recovery (d)* 16 (13-21) 29 (21-35) <0.001
Platelet
recovery (d)* 24 (17-35) 51 (32-59) 0.011
100d TRM† 3 [13% (3-34)] 5 [19% (7-39)] 0.71
aGVHD (2-4)† 5 [22% (7-44)] 5 [19% (7-39)] 0.83
CGVHD (in at
risk)† 8 [40% (19-64)] 7 [33% (15-57)] 0.66
Relapse at 3
yrs† 5 [22% (7-44)] 4 [15% (4-35)] 0.72
3 yr EFS† 60% (40-80) 61% (42-80) 0.72
*Median (range); †% (95% CI).
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TOTAL BODY IRRADIATION, FLUDARABINE, MELPHALAN AND ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR AD-
VANCED PEDIATRIC HEMATOLOGIC MALIGNANCIES
Petropoulos, D. M.D. Anderson Cancer Center, Houston, TX
The Fludarabine (F)-Melphalan (M) reduced-intensity prepara-
tive regimen has been successfully used in adults for allogeneic
hematopoietic stem cell transplant (HSCT). We evaluated the
efﬁcacy and toxicity of adding 9 Gy of total body irradiation (TBI),
in three single daily fractions of 3 Gy, to the reduced intensity
regimen of ﬂudarabine 30 mg/m2 i.v.  4 days and melphalan 140
mg/m2 i.v.  1 day in advanced pediatric hematologic malignan-
cies. GVHD prophylaxis consisted of tacrolimus and mini-meth-
otrexate. No anti-thymocyte globulin was used. Twenty-two acute
lymphoblastic leukemia (ALL), 6 acute myeloid leukemia (AML),
and 1 anaplastic large-cell lymphoma patients were transplanted.
Thirteen of these were beyond second remission, and ﬁve had prior
HSCT. Twenty-one donors were unrelated: 1-2 antigen mis-
matched cord blood (CB) for 19 patients, bone marrow in one and
peripheral blood stem cells (PBSC) in one. Three of the 8 related
donors were genotypically disparate. Oral mucositis and diarrhea
were the most common side effects seen. Twenty-seven patients
achieved neutrophil engraftment at a median of 16 days (range
11-35), and 23 had platelet engraftment (median 42 days, range
14-200). One patient had primary graft failure. Seven patients (all
with ALL) died of non-relapse causes in the ﬁrst 100 days. Six of 27
evaluable patients developed grade III-IV acute GVHD and three
chronic GVHD. Nine patients (7 with ALL) relapsed at a median
of 8 months post-transplant (range 2-54). With a median follow-up
of 55 (range 25-88) months, 7 of 22 ALL, 5 of 6 AML, 1 of 1
lymphoma patients are alive and in remission. This includes eight
of the 19 CBT recipients. The regimen of TBI, F and M allows the
engraftment of allogeneic HSC (including mismatched unrelated
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cord blood units) in heavily pretreated pediatric patients with
hematologic malignancies, without the inclusion of ATG. Its efﬁ-
cacy in AML deserves further evaluation.
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MULTIPOTENT ADULT STEM CELLS
Verfaillie, C.M., Jiang, Y., Luttun, A., Ross, J., Oki, M., Seraﬁni, M.,
Buckley, S., Laksmipathy, U., Zeng, L., Tolar, J., Blazar, B. Stem Cell
Institute, University of Minnesota
The quintessential stem cell is the embryonal stem (ES) cell
which has unlimited self-renewal and multipotent differentiation
potential. Stem cells have also been identiﬁed in most tissues.
Compared with ES cells, tissue speciﬁc stem cells have less self-
renewal ability and, although they differentiate into multiple lin-
eages, they are not multipotent. A large number of recent pub-
lished studies have suggested that tissue speciﬁc stem cells may
have the ability to generate cells of tissues from unrelated organs.
We have identiﬁed a population of primitive cells in normal hu-
man, rodent, and swine post-natal tissues that have, at the single
cell level, multipotent differentiation and extensive proliferation
potential, which we named Multipotent Adult Progenitor Cell or
MAPC. Improved isolation processes have now generated cells
with Oct4 levels that vastly exceed the levels in MAPCs previously
published. This improvement has lead to signiﬁcantly greater dif-
ferentiation ability and signiﬁcantly greater in vivo engraftment
ability.
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WHARTON’S JELLY STEM CELLS: ISOLATION, EXTRACTION AND PRE-
LIMINARY CHARACTERIZATION
Cetrulo, C. Tufts University School of Medicine, Boston, MA
At the 2nd Annual International Cord Blood Symposium held in
May 2004, John Wagner stated that one of the goals for the
transplant community was to improve engraftment through three
novel approaches. Double unit transplantation, ex vivo expansion,
and a co-infusion of mesenchymal stem cells with hematopoietic
stem cells harvested from the cord blood. The combination of
umbilical cord matrix cells and the hematopoietic cord blood stem
cells fulﬁll these three requirements and may possibly lead to
quicker engraftment times for patients receiving cord blood trans-
plantation. Everyone is or should be interested in the placenta
because of the sources of stem cells that it provides. Stem cells can
be found in the placenta, amniotic ﬂuid, umbilical vein, decidua,
cord blood and also the Wharton’s Jelly (Umbilical Cord Matrix,
UCM). Characteristics of UCM stem cells include: Matrix Recep-
tors CD44, CD105, Integrin Markers CD29, CD51, MSC Mark-
ers SH2, SH3, and do not express CD34 and CD45. UCMs do not
express the Costimulatory, B7-1, B7-2 or CD40 or CD401. UCMs
are found to be negative for Class I MHC-/MHC-Class II in 95%
of the population following passage and cryopreservation. These
cells also express Oct-4. Wharton’s Jelly contains stem cells that
are a rich source of primitive multipotent mesenchymal cells with
high telomerase activity responsible for their self-renewal capacity
and immortality and have the capability to differentiate into bone,
cartilage, muscle cells (cardiac) and nerve cells. The goal is to
develop these cells as accessory supporting cells for cord blood
transplantation.
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INTERNATIONAL STANDARDS AND ACCREDITATION IN CORD BLOOD
BANKING AND CELLULAR THERAPY: THE FOUNDATION FOR THE AC-
CEDITATION OF CELLULAR THERAPY
Warkentin, P.I. University of Nebraska Medical Center, Omaha, NE
The Foundation for the Accreditation of Cellular Therapy
(FACT) was founded in 1996 by the American Society for Blood
and Marrow Transplant and the International Society for Cellular
Therapy to establish standards and a voluntary inspection and
accreditation program for quality patient medical care and labora-
tory practice in hematopoietic cellular therapy, while preserving
the essential research environment. Two hundred twenty nine
hematopoietic cell transplant programs have applied for accredita-
tion; and currently one hundred thirty two have achieved accred-
itation. FACT collaborated to develop international standards for
cord blood banking with NETCORD, a foundation of member
cord blood banks established to globally unite the supply and
demand of umbilical cord blood and to maintain world-wide stan-
dards and a system of quality approval in the area of umbilical cord
blood. The goals of NETCORD-FACT International Standards
for Cord Blood Collection, Processing, Testing, Banking, Selec-
tion and Release are to promote quality practices and to consis-
tently assure provision of quality cord blood units for transplanta-
tion. NETCORD-FACT Standards encompass all phases of cord
blood for transplantation. A Cord Blood Bank is deﬁned as an
integrated team responsible for the collection, processing, testing,
banking, selection and release of CB units for transplantation. No
speciﬁc bank structure is required, however, there must be a pro-
cess to meet all of the standards. Standards require all cord blood
banks to maintain a comprehensive Quality Management Program
overseen by a designated individual; to utilize validated methods,
supplies, reagents, and equipment; to document personnel qualiﬁ-
cation, training and continued competence; and to maintain the
details of clinical outcome, including at least viability and cell yield
of the CB unit, adverse events during infusion, and recipient
engraftment, survival, graft versus host disease and chimerism.
These Standards do not encompass the clinical use of cord blood
units, which is covered in the FACT clinical standards for trans-
plant programs. FACT-NETCORD accreditation is voluntary,
open to both public and private banks, and intended to be educa-
tional and collegial, to raise the standard of quality in all banks.
Currently, thirty-nine Cord Blood Banks from the United States,
United Kingdom, Europe and Asia have applied for FACT-NET-
CORD accreditation. Of these, 11 have completed the on-site
inspection and seven are fully accredited.
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AABB STANDARDS AND ACCREDITATION FOR CORD BLOOD
Loper, K.1, Otter, J.1, Rapp, H.1, McMannis, J. (presenter)2. 1. AABB,
Bethesda, MD; 2. M.D. Anderson Medical Center, Houston, TX
For almost 60 years, the AABB (formerly American Association
of Blood Banks) has been the preeminent leader in transfusion
medicine with 8,000 individual members and 1,800 institutional
members. AABB had applied its extensive experience in standard
setting, education and accreditation programs to related biological
therapies including cord blood collection and processing. AABB is
dedicated to ensuring that patients who provide or are treated with
cord blood receive the best care, with a strong focus on the
laboratory processes and the cord blood product itself including
post-transplant outcomes. In 2004 AABB incorporated its cord
blood standards into the Standards for Cellular Therapy Services.
These standards integrate quality management systems with tech-
nical requirements. These standards apply to donor selection, eli-
gibility, product processing, storage and issuance, including out-
comes data collection. Standards are revised every 2 years but
interim or emergent standards can be issued at any time as circum-
stances warrant. AABB’s accreditation program is systems based
and assesses compliance to requirements in the Standards via the
collection of objective evidence. Non-conformances must be
linked to a speciﬁc standard and when identiﬁed, require the
formulation and implementation of a corrective action plan. The
assessment team is composed of a lead assessor and team members
with 5 years experience in HPC and cord blood activities. As-
sessors undergo initial training and are required to maintain spe-
ciﬁc levels of continuing education in designated subjects. Cur-
rently, there are 22 AABB accredited cord blood banks, both public
and private, national and international. Due to the signiﬁcant
improvements in the new standards, AABB began reassessing cord
blood facilities against the new standards May 1, 2005. AABB
commends Congress and the IOM for commissioning the Institute
of Medicine Cord Blood Study Committee and its recommenda-
tion for a national, federally funded program. AABB supports
consistency in standard setting and continues to work with orga-
nizations to establish uniform cord blood standards for all cord
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